EP300 and esophageal cancer: The mutation data include the following: PTEN (11.7 and 8.7%) in breast and colorectal cancer; ATM (18.0 and 11.1%) in liver and esophagus cancer; CDKN2A (11.1 and 9.6%) in pancreas and head and neck cancer; and ATM (50.0%), ATR (41.7%), PTEN (83.3%), RB1 (41.7%), and EP300 (33.3%), which is an acetyltransferase (HAT) associated with TP53 acetylation [32], in uterine cancer.